---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000097"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-07-11T23:59:59+00:00"
generated_at: "2026-05-31T21:46:53.849600+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nurix posts Q2 net loss $44.5M; cash rises to $452.5M; NX-5948 ORR 69.2% in CLL

## Summary
- Net loss $44.5M ($0.71/sh) vs $24.3M ($0.45/sh) YoY; collaboration revenue $12.1M (+13% YoY).
- Cash and marketable securities $452.5M as of May 31, 2024, up from $254.3M after $188.7M public offering.
- NX-5948 Phase 1a/b data: ORR 69.2% in heavily pretreated CLL patients; plans for pivotal trial in 2025.
- Appointed Paula O'Connor as CMO and Pasit Phiasivongsa as CTO to lead clinical and CMC operations.
- Entered into Amendment No.1 to equity distribution agreement allowing up to $150M ATM offerings.

## SEC filing metadata
- accession: 0001549595-24-000097
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-07-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000097/0001549595-24-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000097/nrix-20240711.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000097
- JSON: https://secwatch.observer/filing/0001549595-24-000097.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.